Aromatase inhibitor-induced musculoskeletal symptoms in foot and ankle surgery

Third-generation aromatase inhibitors (AIs) are the cornerstone of the management of hormone receptor-positive breast cancer. Annually, approximately 4,700 Danish women are diagnosed with breast cancer. A large number of patients treated with long-term AI experience arthralgias and myalgias, described in the literature as AI-induced musculoskeletal symptoms (AIMSS). This report aims to summarise the existing knowledge on the syndrome and present cases of AIMSS referred with refractory foot pain to raise awareness of the syndrome as a diagnostic pitfall.

In this study, the electronic patient journals of five potential cases of AIMSS were examined. The patients were all Caucasian females with breast cancer receiving treatment with anti-oestrogenic medication.

AIMSS was found to be the most probable explanation in all five cases. AI-associated musculoskeletal syndrome is reported in 30-70% of patients in AI treatment. Among the five summarised cases, no clinically relevant additional information was gained from extensive imaging. The symptoms led to surgery at our department, in one case with no effect.

AIMSS may affect all joints, including the ankles and feet. Lack of patient information regarding AIMSS can lead to unnecessary, time-consuming, costly and potentially harmful diagnostic procedures and treatment.

None.

Not relevant.